381 related articles for article (PubMed ID: 11791176)
1. Functional roles of Akt signaling in mouse skin tumorigenesis.
Segrelles C; Ruiz S; Perez P; Murga C; Santos M; Budunova IV; Martínez J; Larcher F; Slaga TJ; Gutkind JS; Jorcano JL; Paramio JM
Oncogene; 2002 Jan; 21(1):53-64. PubMed ID: 11791176
[TBL] [Abstract][Full Text] [Related]
2. PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways.
Yao D; Alexander CL; Quinn JA; Porter MJ; Wu H; Greenhalgh DA
Cancer Res; 2006 Feb; 66(3):1302-12. PubMed ID: 16452183
[TBL] [Abstract][Full Text] [Related]
3. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.
Larcher F; Robles AI; Duran H; Murillas R; Quintanilla M; Cano A; Conti CJ; Jorcano JL
Cancer Res; 1996 Dec; 56(23):5391-6. PubMed ID: 8968091
[TBL] [Abstract][Full Text] [Related]
5. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation.
Suzuki A; Itami S; Ohishi M; Hamada K; Inoue T; Komazawa N; Senoo H; Sasaki T; Takeda J; Manabe M; Mak TW; Nakano T
Cancer Res; 2003 Feb; 63(3):674-81. PubMed ID: 12566313
[TBL] [Abstract][Full Text] [Related]
6. Activated Akt-1 in specific cell populations during multi-stage skin carcinogenesis.
Affara NI; Schanbacher BL; Mihm MJ; Cook AC; Pei P; Mallery SR; Trempus CS; Bauer JA; Robertson FM
Anticancer Res; 2004; 24(5A):2773-81. PubMed ID: 15517884
[TBL] [Abstract][Full Text] [Related]
7. Ochratoxin A-induced cell proliferation and tumor promotion in mouse skin by activating the expression of cyclin-D1 and cyclooxygenase-2 through nuclear factor-kappa B and activator protein-1.
Kumar R; Alam S; Chaudhari BP; Dwivedi PD; Jain SK; Ansari KM; Das M
Carcinogenesis; 2013 Mar; 34(3):647-57. PubMed ID: 23172667
[TBL] [Abstract][Full Text] [Related]
8. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.
Wang J; Ouyang W; Li J; Wei L; Ma Q; Zhang Z; Tong Q; He J; Huang C
Cancer Res; 2005 Aug; 65(15):6601-11. PubMed ID: 16061640
[TBL] [Abstract][Full Text] [Related]
9. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.
Tognon C; Garnett M; Kenward E; Kay R; Morrison K; Sorensen PH
Cancer Res; 2001 Dec; 61(24):8909-16. PubMed ID: 11751416
[TBL] [Abstract][Full Text] [Related]
10. The progression in the mouse skin carcinogenesis model correlates with ERK1/2 signaling.
Katsanakis KD; Gorgoulis V; Papavassiliou AG; Zoumpourlis VK
Mol Med; 2002 Oct; 8(10):624-37. PubMed ID: 12477973
[TBL] [Abstract][Full Text] [Related]
11. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
12. PI-3K/Akt pathway-dependent cyclin D1 expression is responsible for arsenite-induced human keratinocyte transformation.
Ouyang W; Luo W; Zhang D; Jian J; Ma Q; Li J; Shi X; Chen J; Gao J; Huang C
Environ Health Perspect; 2008 Jan; 116(1):1-6. PubMed ID: 18197291
[TBL] [Abstract][Full Text] [Related]
13. Strain-dependent differences in malignant conversion of mouse skin tumors is an inherent property of the epidermal keratinocyte.
Woodworth CD; Michael E; Smith L; Vijayachandra K; Glick A; Hennings H; Yuspa SH
Carcinogenesis; 2004 Sep; 25(9):1771-8. PubMed ID: 15105299
[TBL] [Abstract][Full Text] [Related]
14. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis.
Casanova ML; Larcher F; Casanova B; Murillas R; Fernández-Aceñero MJ; Villanueva C; Martínez-Palacio J; Ullrich A; Conti CJ; Jorcano JL
Cancer Res; 2002 Jun; 62(12):3402-7. PubMed ID: 12067982
[TBL] [Abstract][Full Text] [Related]
15. Alterations in epidermal biochemistry as a consequence of stage-specific genetic changes in skin carcinogenesis.
Yuspa SH; Kilkenny A; Cheng C; Roop D; Hennings H; Kruszewski F; Lee E; Strickland J; Greenhalgh DA
Environ Health Perspect; 1991 Jun; 93():3-10. PubMed ID: 1773799
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis.
Gotoh J; Obata M; Yoshie M; Kasai S; Ogawa K
Carcinogenesis; 2003 Mar; 24(3):435-42. PubMed ID: 12663502
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of PTEN/MMAC1 and decreased activation of Akt in human papillomavirus-infected laryngeal papillomas.
Zhang P; Steinberg BM
Cancer Res; 2000 Mar; 60(5):1457-62. PubMed ID: 10728713
[TBL] [Abstract][Full Text] [Related]
18. A genetic variant of Aurora kinase A promotes genomic instability leading to highly malignant skin tumors.
Torchia EC; Chen Y; Sheng H; Katayama H; Fitzpatrick J; Brinkley WR; Caulin C; Sen S; Roop DR
Cancer Res; 2009 Sep; 69(18):7207-15. PubMed ID: 19738056
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential.
Chung TW; Lee YC; Kim CH
FASEB J; 2004 Jul; 18(10):1123-5. PubMed ID: 15132991
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of Akt-induced keratinocyte transformation.
Segrelles C; Moral M; Lara MF; Ruiz S; Santos M; Leis H; García-Escudero R; Martínez-Cruz AB; Martínez-Palacio J; Hernández P; Ballestín C; Paramio JM
Oncogene; 2006 Feb; 25(8):1174-85. PubMed ID: 16247457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
